<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic yield of familial pancreatic cancer screening and surveillance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic yield of familial pancreatic cancer screening and surveillance</h1>
<div class="graphic"><div class="figure"><div class="ttl">Diagnostic yield of familial pancreatic cancer screening and surveillance</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Study</td> <td class="subtitle1">High-risk group</td> <td class="subtitle1">Imaging tests</td> <td class="subtitle1">Diagnostic yield*</td> </tr> <tr> <td>Brentnall 1999; <span style="white-space: nowrap;">n = 14</span></td> <td>FPC</td> <td>EUS + ERCP + CT</td> <td>7/14 (50%)<sup>¶</sup></td> </tr> <tr> <td>Kimmey 2002; <span style="white-space: nowrap;">n = 46<sup>Δ</sup></span></td> <td>FPC</td> <td>EUS; ERCP<sup>◊</sup></td> <td>12/46 (26%)<sup>¶</sup></td> </tr> <tr> <td>Canto 2004; <span style="white-space: nowrap;">n = 38</span></td> <td>FPC, PJS</td> <td>EUS; ERCP<sup>◊</sup>, EUS-FNA<sup>◊</sup>, CT<sup>◊</sup></td> <td>2/38 (5.3%)<sup>¶</sup></td> </tr> <tr> <td>Canto 2006; <span style="white-space: nowrap;">n = 78</span></td> <td>FPC, PJS</td> <td>EUS; CT<sup>◊</sup>, EUS-FNA<sup>◊</sup>, ERCP<sup>◊</sup></td> <td>8/78 (10.2%)<sup>¶</sup><sup>§</sup></td> </tr> <tr> <td>Poley 2009; <span style="white-space: nowrap;">n = 44</span></td> <td>FPC, BRCA, PJS, CDKN2A, p53, hereditary pancreatitis</td> <td>EUS; CT<sup>◊</sup>, MRI<sup>◊</sup></td> <td>10/44 (23%)</td> </tr> <tr> <td>Langer 2009; <span style="white-space: nowrap;">n = 76</span></td> <td>FPC, BRCA</td> <td>EUS + MRCP; EUS-FNA<sup>◊</sup></td> <td>1/76 (1.3%)<sup>¶</sup><sup>§</sup></td> </tr> <tr> <td>Verna 2010; <span style="white-space: nowrap;">n = 51</span></td> <td>FPC, BRCA, CDKN2A</td> <td>EUS and/or MRCP</td> <td>6/51 (12%)<sup>¶</sup></td> </tr> <tr> <td>Ludwig 2011; <span style="white-space: nowrap;">n = 109</span></td> <td>FPC, BRCA</td> <td>MRCP; EUS<sup>◊</sup>, EUS-FNA<sup>◊</sup></td> <td>9/109 (8.3%)<sup>§</sup></td> </tr> <tr> <td>Vasen 2011; <span style="white-space: nowrap;">n = 79</span></td> <td>CDKN2A</td> <td>MRI/MRCP</td> <td>14/79 (18%)<sup>¶</sup></td> </tr> <tr> <td>Al-Sukhni 2011; <span style="white-space: nowrap;">n = 262</span></td> <td>FPC, BRCA, PJS, CDKN2A, hereditary pancreatitis</td> <td>MRI; CT<sup>◊</sup>, EUS<sup>◊</sup>, ERCP<sup>◊</sup></td> <td>19/262 (7.3%)<sup>§</sup></td> </tr> <tr> <td>Schneider 2011<sup>¥</sup>; <span style="white-space: nowrap;">n = 72</span></td> <td>FPC, BRCA, PALB2</td> <td>EUS+MRCP</td> <td>11/72 (15%)<sup>§</sup></td> </tr> <tr> <td>Canto 2012; <span style="white-space: nowrap;">n = 216</span></td> <td>FPC, BRCA, PJS</td> <td>CT, MRI/MRCP, EUS; ERCP<sup>◊</sup></td> <td>5/216 (2.3%)<sup>¶</sup> – 92/216 (42%)</td> </tr> <tr> <td>Harinck 2015; <span style="white-space: nowrap;">n = 139</span></td> <td>FPC, BRCA, PJS, CDKN2A</td> <td>MRI, EUS</td> <td>11/139 (8%)<sup>§</sup></td> </tr> <tr> <td>Vasen 2016; <span style="white-space: nowrap;">n = 411</span></td> <td>FPC, BRCA, PALB2, CDKN2A</td> <td>MRI, MRCP, EUS</td> <td>32/411 (7.8%)<sup>¶</sup><sup>§</sup></td> </tr> <tr> <td>Overbeek 2021; <span style="white-space: nowrap;">n = 366</span></td> <td>FPC, CDKN2A, BRCA, PALB2, STK11/LKB1, TP53, ATM</td> <td>EUS and MRI/MRCP</td> <td>10/165 (6%) in mutation carriers; 0/201 in FPC kindreds<sup>‡</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">FPC: familial pancreatic cancer; EUS: endoscopic ultrasound; ERCP: endoscopic retrograde cholangiopancreatography; CT: computed tomography; PJS: Peutz-Jeghers syndrome; EUS-FNA: endoscopic ultrasound-guided fine needle aspiration; BRCA: breast-related cancer; CDKN2A: cyclin-dependent kinase inhibitor 2A; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; IPMN: intraductal papillary mucinous neoplasms.<br/>
* Yield is defined as the detection of any pathologically proven (pre)malignant lesion (≥PanIN2/IPMN and pancreatic adenocarcinoma) and lesions that are morphologically suspicious for branch-duct IPMNs.<br/>
¶ Includes only pathologically proven pancreatic neoplasms (histology or cytology).<br/>
Δ Continuation of Brentnall 1999, included 14 high-risk individuals from Brentnall 1999.<br/>
<span class="lozenge">◊</span> Test performed only as an additional test for detected abnormalities.<br/>
§ Includes baseline and follow-up.<br/>
¥ Continuation of Langer 2009, includes high-risk individuals from this series.<br/>
‡ None of the cases were FPC kindreds. Estimated cumulative incidence of pancreatic ductal adenocarcinoma in mutation carriers was 6.5% at 5 years and 9.3% at 10 years.</div><div id="graphicVersion">Graphic 107901 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
